Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023

Technology Advances and New Radiopharmaceuticals Maintain the Industry on a Growth Track

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

Molecular imaging can easily be described as the next frontier of medical imaging. In an era of value-based reimbursement, molecular imaging is set to play a significant role in quicker diagnosis, more accurate disease staging, and selection of targeted treatments. Launch of new radiopharmaceuticals across clinical areas other than cardiology and oncology such as neurology and orthopedics is also expected to drive greater adoption of molecular imaging as part of clinical care pathways.

However, molecular imaging continues to face several challenges, notably the high cost of molecular imaging modalities and image scans, competition from lower cost modalities such as CT and MRI, and concerns over future supply of Tc-99m, a key SPECT radiopharmaceutical used for cardiac scans. This study analyzes existing trends in the hybrid molecular imaging and diagnostic radiopharmaceuticals markets with an emphasis on understanding strategies employed by market participants to address these myriad challenges. It also assesses both these markets in the context of changing regulatory and reimbursement policies in order to provide future market trends. This analysis will be critical in helping market participants create long-term viable strategies in order to remain competitive and ensure continuous innovation.

This deliverable assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies.

Table of Contents

1. Research Methodology
Research Methodology
Scope of This Study
2. Executive Summary—Molecular Imaging
Key Findings
Market Engineering Measurements—PET/CT
Market Engineering Measurements—SPECT/CT
Market Engineering Measurements—PET/MR
3. Executive Summary—Radiopharmaceuticals
Key Findings
Market Engineering Measurements—PET
Market Engineering Measurements—SPECT
4. Market Overview
Scope of the Study—Molecular Imaging
Scope of the Study—Radiopharmaceuticals
Molecular Imaging—Segmentation
Molecular Imaging—Definition
Shift in Focus from Standalone to Hybrid Imaging
Radiopharmaceuticals—Definitions
Segmentation of Radiopharmaceuticals
Distribution of Radiopharmaceuticals
US Radiopharmacy Facility Landscape 2016
5. Drivers and Restraints—Total Molecular Imaging Equipment Market
Market Drivers
Improved quantitation accuracy makes molecular imaging more reliable
Molecular imaging will play an increasingly larger role in personalized medicine
Advances in molecular imaging technologies
Improvements in Quantitation Accuracy
Role of Molecular Imaging in Personalized Medicine
Molecular Imaging Entering Into New Therapeutic Areas
Market Restraints
Increasing cost of hybrid molecular imaging modalities
Mergers and acquisitions between hospitals and other hospitals
Changing procurement practices by hospitals
Affordability of Hybrid Modalities Will Remain Key Issue
Consolidations of Healthcare Providers
Changing Hospital Procurement Models
6. PET/CT Equipment Segment
Market Engineering Measurements
Unit Shipment Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
7. SPECT/CT Equipment Segment
Market Engineering Measurements
Unit Shipment Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
8. PET/MR Equipment Segment
Market Engineering Measurements
Unit Shipment Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
9. Key Products and Participants
Analysis of Hybrid Molecular Imaging Products
Actively Marketed PET/CT Products in 2016
Actively Marketed PET/MR Products in 2016
Actively Marketed SPECT/CT Products in 2016
10. Latest Trends Among the Big Three Competitors—Philips Healthcare
Digital PET—The Next Chapter in Nuclear Imaging
11. GE Healthcare
GE Healthcare—Key Technology Trends
GE Debuts DiscoveryTM MI PET/CT at SNMMI 2016
Launch of Discovery IQ PET/CT by GE
GE Launches First General Purpose Digital SPECT/CT
12. Siemens Healthineers
Siemens Debuts Mobile Biograph Horizon PET/CT
Siemens Debuts Latest Version of syngo.via
13. Companies to Look Out For
NeuSoft
Toshiba America Medical Systems
Molecular Dynamics
UltraSPECT
14. Other Issues Impacting Growth Of Molecular Imaging
Upgradeability and Intra Modality Competition
Nuclear Medicine Physicians Face Employment Challenges
15. Key Technology and Industry Trends
Technology Trends—PET/CT & SPECT/CT
Industry Trends—Advancements in Brain Imaging Using SPECT
Industry Trends—PET Scanning and Alzheimer’s Disease
Industry Trends—CMS Approves Funding for PET Amyloid Study
Industry Trends—Myocardial Perfusion Imaging: PET vs. SPECT
16. Drivers and Restraints—Total Radiopharmaceuticals Market
Market Drivers
Development of new PET and SPECT
Greater adoption of cyclotron-based approaches
Reactor-based supply of Mo-99
Development of New Radiopharmaceuticals
Adopting a Cyclotron-based Approach
Mo-99 Production—Key Challenges and Potential Solutions
Market Restraints
Pricing of Tc-99m is per unit dose and not by amount
High entry barriers are limiting the number of market participants
Pricing and Reimbursement of Tc-99m—Key Challenges
High Entry Barriers Limit the Number of Participants
17. PET Radiopharmaceuticals Segment
Market Engineering Measurements
Procedure Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
18. SPECT Radiopharmaceuticals Segment
Market Engineering Measurements
Procedure Forecast
Revenue Forecast
Trend Analysis
Market Share
Market Share Analysis
19. Key Products and Participants
Analysis of PET and SPECT Radiopharmaceuticals
Key Market Participants and Main Product Lines
20. Key Companies to Look Out For
Siemens PETNET
IBA Molecular
Ionetix
21. Key Industry Trends
Jubilant Draximage Develops Rubidium Generator
Northstar Medical Isotopes to Produce Mo-99
FDA Approves Gallium 68 Dotatate Kit—NETSPOT
FDA Approves Axumin PET Radiopharmaceutical
Axumin—Safety and Efficacy Parameters
CMS Rejection of NaF—18 PET Scan Reimbursement
Cardiac PET Perfusion Agents Industry—A Snapshot
22. Role of New Radiopharmaceuticals in Oncology
Role of Radiopharmaceuticals in Oncology Clinical Trials
18F-CFA—The Next Frontier in Cancer Treatment
New PET Tracers for Clinical Use in Oncology
23. The Last Word
The Last Word—3 Big Predictions: Molecular Imaging
The Last Word—3 Big Predictions: Radiopharmaceuticals
Legal Disclaimer
24. Appendix
Glossary of Terms—Molecular Imaging
Glossary of Terms—Radiopharmaceuticals
Market Engineering Methodology
25. Medicare Hospital Outpatient Prospective Payment System (HOPPS)
Reimbursement of Procedures Involving Use of Radiopharmaceuticals and Molecular Imaging Modalities
Reimbursed Radiopharmaceuticals Billing Codes

Infographic



List of Figures & Charts

1. Total Molecular Imaging Equipment Market: Key Market Drivers, US, 2017–2023
2. Total Molecular Imaging Equipment Market: Key Market Restraints, US, 2017–2023
3. PET/CT Equipment Segment: Market Engineering Measurements, US, 2016
4. SPECT/CT Equipment Segment: Market Engineering Measurements, US, 2016
5. PET/MR Equipment Segment: Market Engineering Measurements, US, 2016
6. Total Radiopharmaceuticals Market: Key Market Drivers, US, 2017–2023
7. Total Radiopharmaceuticals Market: Key Market Restraints, US, 2017–2023
8. PET Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016
9. SPECT Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016


1. PET/CT Equipment Segment: Market Engineering Measurements, US, 2016
2. SPECT/CT Equipment Segment: Market Engineering Measurements, US, 2016
3. PET/MR Equipment Segment: Market Engineering Measurements, US, 2016
4. PET Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016
5. SPECT Radiopharmaceuticals Segment: Market Engineering Measurements, US, 2016
6. PET/CT Equipment Segment: Unit Shipment Forecast, US, 2013–2023
7. PET/CT Equipment Segment: Revenue Forecast, US, 2013–2023
8. PET/CT Equipment Segment: Percent of Sales, US, 2016
9. SPECT/CT Equipment Segment: Unit Shipment Forecast, US, 2013-2023
10. SPECT/CT Equipment Segment: Revenue Forecast, US, 2013–2023
11. SPECT/CT Equipment Segment: Percent of Sales, US, 2016
12. PET/MR Equipment Segment: Unit Shipment Forecast, US, 2013–2023
13. PET/MR Equipment Segment: Revenue Forecast, US, 2013–2023
14. PET/MR Equipment Segment: Percent of Sales, US, 2016
15. PET Radiopharmaceuticals Segment: Procedure Forecast, US, 2013–2023
16. PET Radiopharmaceuticals Segment: Revenue Forecast, US, 2013-2023
17. PET Radiopharmaceuticals Segment: Percent of Sales, US, 2016
18. SPECT Radiopharmaceuticals Segment: Procedure Forecast, US, 2013–2023
19. SPECT Radiopharmaceuticals Segment: Revenue Forecast, US, 2013–2023
20. SPECT Radiopharmaceuticals Segment: Percent of Sales, US, 2016



Keyword1

Keyword2

Keyword3

Related Research

Release Date : 06-Nov-17

Region : North America

Release Date : 30-Oct-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 15-Nov-16

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.